Completed PHASE2 INTERVENTIONAL 1-arm NCT03999684

A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

A Phase II Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

Sponsor: Adenoid Cystic Carcinoma Research Foundation

Interventions Tretinoin

Updated 10 times since 2019 Last updated: Jan 19, 2023 Started: Aug 5, 2019 Primary completion: Apr 15, 2020 Completion: Apr 15, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adenoid Cystic Carcinoma and is currently completed. Adenoid Cystic Carcinoma Research Foundation leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2023 — Feb 2023 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Sep 2021 — Dec 2022 [monthly]

Completed PHASE2
Jan 2021 — Sep 2021 [monthly]

Completed PHASE2
Aug 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Sep 2019 — Aug 2020 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2019 — Sep 2019 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Adenoid Cystic Carcinoma Research Foundation
Dana-Farber Cancer Institute
The V Foundation

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States